Pharma Focus Asia

Saniona ion channel research collaboration with Boehringer Ingelheim advances to next stage

Monday, March 21, 2022

Saniona, a clinical stage biopharmaceutical company focused on rare diseases, today announced that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the next stage.

“After successful completion of target validation, library screening and generation of selective hits, Saniona and Boehringer Ingelheim have agreed to progress our ongoing ion channel research collaboration into the ‘hit-to-lead’ stage,” said Jørgen Drejer, Founder and Chief Scientific Officer of Saniona. “We look forward to continuing our partnership with Boehringer Ingelheim scientists as we work together to identify novel ion channel modulators to treat cognitive deficits in schizophrenia.”

Saniona and Boehringer Ingelheim entered into the ongoing research collaboration in 2020. The collaboration is focused on a novel, undisclosed CNS ion channel target for schizophrenia. Saniona receives ongoing research funding and may receive up to €76.5 million in milestone payments as well as royalties on worldwide net sales.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024